Coming May 2025
Get Early Access
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
From TechCrunch
By Marina Temkin
May 9, 2024
For cancer patients, medicines administered in clinical trials can help save or extend lives.
But despite thousands of trials in the United States each year, only 3% to 5% of eligible patients enroll in investigations of new treatments.
Triomics, a generative AI startup, claims it can significantly reduce the time it takes doctors to match patients with trials.
Doctors’ recommendations are often key to getting patients enrolled. However, busy oncologists and nurses often lack the time to learn about all the clinical trials that may be right for their patients.
I am not a doctor, so I don’t know about the day-to-day challenges of oncology medical staff. But I unfortunately know from personal experience how hard it is to find clinical trials for cancer patients. When my father was sick, I spent countless hours poring over clinicaltrials.gov, a website and database that lists thousands of ongoing trials. And just in March, I spent half a Saturday trying to find a clinical trial for a friend who has stage IV cancer. Her doctor only offered one trial, so she asked me if there were other options.
Since most clinical trials have complex criteria, there are often dozens of factors such as stage of cancer, mutations and previous treatments for eligibility. Medical staff often need hours to manually review a patient’s medical record to find a fitting clinical trial. But due to a shortage of oncology professionals, many cancer patients aren’t offered to participate or they miss their eligibility window.
Triomics was founded by former MIT biotech researcher Sarim Khan and AI scientist at Adobe Hrituraj Singh. The pair, who have been friends since college, decided to build Triomics in 2021 after realizing that advances in generative AI and LLMs could help extract data from electronic health records (EHR) to help find appropriate clinical trials for cancer patients in minutes instead of hours.
Khan and Singh entered Y Combinator in the winter of 2021 and proceeded to work on an LLM built specifically for cancer centers and oncology departments in hospital systems.
Three years later, Triomics says six cancer centers and hospitals are actively using or piloting its LLM, and it plans to double that number by the end of the year. And now the company has raised a $15 million Series A from Lightspeed, Nexus Venture Partners, General Catalyst and Y Combinator to help it continue to develop its platform and roll it out to new customers.
While reducing how long it takes for patients to be matched with clinical trials may seem like the most immediately valuable application of Triomics software, Khan says that Triomics is a lot more than a clinical trials company. “Doctors use it for several different use cases that I could just go on and on about,” he said.
After Triomics’ LLM, which the company is calling OncoLLM, “reads” the patient’s medical record, the data could be used to help prepare doctors and other medical staff for patient visits or to help submit cancer data with details of organs affected and stage of progressions to state regulatory agencies.
Of course, Triomics isn’t alone in tackling this area. Other startups doing AI clinical trial matching include Deep 6 AI, QuantHealth, Trajectory, among others.
But Khan believes that Triomics is one of the few startups processing large swaths of datasets specifically for cancer centers.
After Shopify bought his last startup, Birk Jernström wants to help developers build one-person unicorns
Sam Altman and “his tech CEO friends” have a betting pool on the year we will see the first one-person billion-dollar company. The idea of a single person reaching a billion-dollar valuation for a startup would have been unthinkable without AI. But single-person, AI-first businesses have been sprouting all over the tech industry and Birk Jernström, CEO of Polar, a “monetization platform to empower one-person unicorns,” is standing by to help them get there. Polar hopes to stand out from other
Jun 18, 2025
A comprehensive list of 2025 tech layoffs
The tech layoff wave is still kicking in 2025. Last year saw more than 150,000 job cuts across 549 companies, according to independent layoffs tracker Layoffs.fyi. So far this year, more than 22,000 workers have been the victim of reductions across the tech industry, with a staggering 16,084 cuts taking place in February alone. We’re tracking layoffs in the tech industry in 2025 so you can see the trajectory of the cutbacks and understand the impact on innovation across all types of companies.
Jun 17, 2025
Unlock purpose-driven growth at TechCrunch All Stage, and get $210 off for 6 more days
T-minus 6 days until TechCrunch All Stage ticket prices rise. From now until June 22 at 11:59 p.m. PT, founders save $210 and investors save $200 on passes. Are you ready to push your startup to the next level? Or are you an investor looking to back the next big breakthrough? Join TC All Stage on July 15 at SoWa Power Station in Boston for the founder summit built for traction and breakout growth. Give your startup a competitive edge. Secure your pass now and save up to $210. Why attend TC All
Jun 17, 2025